Lymphocyte-to-Monocyte Ratio is Associated with the Poor Prognosis of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

References

• Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–387. doi:10.1016/j.ejca.2018.07.00530100160
   PubMed Web of Science ®Google Scholar
• Spring L, Greenup R, Niemierko A, et al. Pathologic complete response after neoadjuvant chemotherapy and long-term outcomes among young women with breast cancer. J Natl Compr Canc Netw. 2017;15(10):1216–1223. doi:10.6004/jnccn.2017.015828982747
   PubMed Web of Science ®Google Scholar
• Fahad Ullah M. Breast cancer: current perspectives on the disease status. Adv Exp Med Biol. 2019;1152:51–64. doi:10.1007/978-3-030-20301-6_431456179
   PubMed Web of Science ®Google Scholar
• Karki R, Man SM, Kanneganti TD. Inflammasomes and cancer. Cancer Immunol Res. 2017;5(2):94–99. doi:10.1158/2326-6066.CIR-16-026928093447
   PubMed Web of Science ®Google Scholar
• Yang L, Lin PC. Mechanisms that drive inflammatory tumor microenvironment, tumor heterogeneity, and metastatic progression. Semin Cancer Biol. 2017;47:185–195. doi:10.1016/j.semcancer.2017.08.00128782608
   PubMed Web of Science ®Google Scholar
• Dominguez C, David JM, Palena C. Epithelial-mesenchymal transition and inflammation at the site of the primary tumor. Semin Cancer Biol. 2017;47:177–184. doi:10.1016/j.semcancer.2017.08.00228823497
   PubMed Web of Science ®Google Scholar
• Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: neutral no more. Nat Rev Cancer. 2016;16(7):431–446. doi:10.1038/nrc.2016.5227282249
   PubMed Web of Science ®Google Scholar
• Franco AT, Corken A, Ware J. Platelets at the interface of thrombosis, inflammation, and cancer. Blood. 2015;126(5):582–588. doi:10.1182/blood-2014-08-53158226109205
   PubMed Web of Science ®Google Scholar
• Peng H-X, Yang L, He B-S, et al. Combination of preoperative NLR, PLR and CEA could increase the diagnostic efficacy for I-III stage CRC. J Clin Lab Anal. 2017;31(5):e22075. doi:10.1002/jcla.22075
   PubMed Web of Science ®Google Scholar
• Liu C, Li X. Stage-dependent changes in albumin, NLR, PLR, and AFR are correlated with shorter survival in patients with gastric cancer. Clin Lab. 2019;65(9). doi:10.7754/Clin.Lab.2019.190132
   Web of Science ®Google Scholar
• Diem S, Schmid S, Krapf M, et al. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017;111:176–181. doi:10.1016/j.lungcan.2017.07.02428838390
   PubMed Web of Science ®Google Scholar
• Cho U, Park HS, Im SY, et al. Prognostic value of systemic inflammatory markers and development of a nomogram in breast cancer. PLoS One. 2018;13(7):e0200936. doi:10.1371/journal.pone.020093630048474
   PubMed Web of Science ®Google Scholar
• Azab B, Mohammad F, Shah N, et al. The value of the pretreatment neutrophil lymphocyte ratio vs. platelet lymphocyte ratio in predicting the long-term survival in colorectal cancer. Cancer Biomark. 2014;14(5):303–312. doi:10.3233/CBM-14041625171472
   PubMed Web of Science ®Google Scholar
• Marin Hernandez C, Pinero Madrona A, Gil Vazquez PJ, et al. Usefulness of lymphocyte-to-monocyte, neutrophil-to-monocyte and neutrophil-to-lymphocyte ratios as prognostic markers in breast cancer patients treated with neoadjuvant chemotherapy. Clin Transl Oncol. 2018;20(4):476–483. doi:10.1007/s12094-017-1732-028785911
   PubMed Web of Science ®Google Scholar
• Lee KH, Kim EY, Yun JS, et al. The prognostic and predictive value of tumor-infiltrating lymphocytes and hematologic parameters in patients with breast cancer. BMC Cancer. 2018;18(1):938. doi:10.1186/s12885-018-4832-530285668
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Loke SY, Lee ASG. The future of blood-based biomarkers for the early detection of breast cancer. Eur J Cancer. 2018;92:54–68. doi:10.1016/j.ejca.2017.12.02529413690
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.01321376230
   PubMed Web of Science ®Google Scholar
• Shi M, Zhao W, Zhou F, et al. Neutrophil or platelet-to-lymphocyte ratios in blood are associated with poor prognosis of pulmonary large cell neuroendocrine carcinoma. Transl Lung Cancer. 2020;9(1):45–54. doi:10.21037/tlcr.2020.01.17
   PubMed Web of Science ®Google Scholar
• Ying HQ, Deng QW, He BS, et al. The prognostic value of preoperative NLR, d-NLR, PLR and LMR for predicting clinical outcome in surgical colorectal cancer patients. Med Oncol. 2014;31(12):305. doi:10.1007/s12032-014-0305-025355641
   PubMed Web of Science ®Google Scholar
• Meng X, Chang Q, Liu Y, et al. Determinant roles of gender and age on SII, PLR, NLR, LMR and MLR and their reference intervals defining in Henan, China: a posteriori and big-data-based. J Clin Lab Anal. 2018;32(2):e22228. doi:10.1002/jcla.22228
   PubMed Web of Science ®Google Scholar
• Rajwa P, Zyczkowski M, Paradysz A, Bujak K, Bryniarski P. Evaluation of the prognostic value of LMR, PLR, NLR, and dNLR in urothelial bladder cancer patients treated with radical cystectomy. Eur Rev Med Pharmacol Sci. 2018;22(10):3027–3037. doi:10.26355/eurrev_201805_1506029863247
   PubMed Web of Science ®Google Scholar
• Yilmaz E, Coskun EI, Sahin N, Ciplak B, Ekici K. MPV, NLR, and platelet count: new hematologic markers in diagnosis of malignant ovarian tumor. Eur J Gynaecol Oncol. 2017;38(3):346–349.29693870
   PubMed Web of Science ®Google Scholar
• Solak Mekic M, Pedisic I, Sobat H, et al. The role of complete blood count parameters in patients with colorectal cancer. Acta Clin Croat. 2018;57(4):624–629. doi:10.20471/acc.2018.57.04.0331168198
   PubMed Web of Science ®Google Scholar
• Xia WK, Liu ZL, Shen D, Lin QF, Su J, Mao WD. Prognostic performance of pre-treatment NLR and PLR in patients suffering from osteosarcoma. World J Surg Oncol. 2016;14:127. doi:10.1186/s12957-016-0889-227125872
   PubMed Web of Science ®Google Scholar
• Koh CH, Bhoo-Pathy N, Ng KL, et al. Utility of pre-treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer. Br J Cancer. 2015;113(1):150–158. doi:10.1038/bjc.2015.18326022929
   PubMed Web of Science ®Google Scholar
• Jia W, Wu J, Jia H, et al. The peripheral blood neutrophil-to-lymphocyte ratio is superior to the lymphocyte-to-monocyte ratio for predicting the long-term survival of triple-negative breast cancer patients. PLoS One. 2015;10(11):e0143061. doi:10.1371/journal.pone.014306126580962
   PubMed Web of Science ®Google Scholar
• Yao M, Liu Y, Jin H, et al. Prognostic value of preoperative inflammatory markers in Chinese patients with breast cancer. Onco Targets Ther. 2014;7:1743–1752. doi:10.2147/OTT.S6965725328407
   PubMed Web of Science ®Google Scholar
• Azab B, Shah N, Radbel J, et al. Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. Med Oncol. 2013;30(1):432. doi:10.1007/s12032-012-0432-423283648
   PubMed Web of Science ®Google Scholar
• Duan J, Pan L, Yang M. Preoperative elevated neutrophil-to-lymphocyte ratio (NLR) and derived NLR are associated with poor prognosis in patients with breast cancer: a meta-analysis. Medicine. 2018;97(49):e13340. doi:10.1097/MD.000000000001334030544398
   PubMed Web of Science ®Google Scholar
• Toiyama Y, Inoue Y, Kawamura M, et al. Elevated platelet count as predictor of recurrence in rectal cancer patients undergoing preoperative chemoradiotherapy followed by surgery. Int Surg. 2015;100(2):199–207. doi:10.9738/INTSURG-D-13-00178.125692418
   PubMed Web of Science ®Google Scholar
• Ishii Y, Hamashima T, Yamamoto S, Sasahara M. Pathogenetic significance and possibility as a therapeutic target of platelet derived growth factor. Pathol Int. 2017;67(5):235–246. doi:10.1111/pin.1253028393435
   PubMed Web of Science ®Google Scholar
• Suner A, Carr BI, Akkiz H, et al. C-reactive protein and platelet-lymphocyte ratio as potential tumor markers in low-alpha-fetoprotein hepatocellular carcinoma. Oncology. 2019;96(1):25–32. doi:10.1159/00049247330336489
   PubMed Web of Science ®Google Scholar
• Zhu Y, Si W, Sun Q, Qin B, Zhao W, Yang J. Platelet-lymphocyte ratio acts as an indicator of poor prognosis in patients with breast cancer. Oncotarget. 2017;8(1):1023–1030. doi:10.18632/oncotarget.1371427906679
   PubMedGoogle Scholar
• Krenn-Pilko S, Langsenlehner U, Thurner EM, et al. The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients. Br J Cancer. 2014;110(10):2524–2530. doi:10.1038/bjc.2014.16324675383
   PubMed Web of Science ®Google Scholar
• Kumarasamy C, Sabarimurugan S, Madurantakam RM, et al. Prognostic significance of blood inflammatory biomarkers NLR, PLR, and LMR in cancer-A protocol for systematic review and meta-analysis. Medicine. 2019;98(24):e14834. doi:10.1097/MD.000000000001483431192906
   PubMed Web of Science ®Google Scholar
• Liu X, Li M, Zhao F, et al. The lymphocyte-monocyte ratio predicts tumor response and survival in patients with locally advanced esophageal cancer who received definitive chemoradiotherapy. Onco Targets Ther. 2017;10:871–877. doi:10.2147/OTT.S12491528243122
   PubMed Web of Science ®Google Scholar
• Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26(2):259–271. doi:10.1093/annonc/mdu45025214542
   PubMed Web of Science ®Google Scholar
• Krstic J, Santibanez JF. Transforming growth factor-beta and matrix metalloproteinases: functional interactions in tumor stroma-infiltrating myeloid cells. Sci World J. 2014;2014:521754. doi:10.1155/2014/521754
   Web of Science ®Google Scholar
• Shand FH, Ueha S, Otsuji M, et al. Tracking of intertissue migration reveals the origins of tumor-infiltrating monocytes. Proc Natl Acad Sci U S A. 2014;111(21):7771–7776. doi:10.1073/pnas.140291411124825888
   PubMed Web of Science ®Google Scholar